Lisata Therapeutics has acquired Marea Therapeutics, a biotech focused on cardioendocrine diseases, through a stock-for-stock deal. The transaction includes a private placement expected to raise about $225 million, which Lisata will use to fund clinical trials for Marea's drug candidates targeting severe hypertriglyceridemia and acromegaly. These trials are set to report results in late 2027. Post-acquisition, Marea's shareholders will hold the majority stake, while Lisata's prior shareholders and new investors will own smaller portions. This move expands Lisata's focus and resources toward advancing important cardioendocrine treatments.
Lisata Therapeutics' acquisition of Marea Therapeutics is the subject here, with Pluang's Health-sector market data providing context. Of 91 priced Health-sector US stocks tradable on Pluang, 65 rose and 26 fell today. Notable movers include DNA at USD 7.77 (+10.06%), CRSP at USD 56.74 (+8.69%, with 35% Sell / 65% Buy order activity), and RXRX at USD 3.46 (+8.62%, with 0% Sell / 100% Buy order activity). These figures are as of Sep 17, 2026 23:42 WIB.
KB Home is set to report its Q3 2026 earnings on September 22, with analysts projecting a 45.3% drop in earnings per share to around $0.89 and a 20.2% decline in revenue to about $1.30 billion compared to last year. The consensus EPS estimate has rec...
An investment of $10,000 in Nebius when it resumed trading in 2024 has grown significantly to approximately $105,000 by 2026. This remarkable increase highlights Nebius's strong market performance over the two-year period. Investors who bought in at ...
W.P. Carey expects to invest over $1.9 billion in 2026, reflecting robust growth in its net lease property portfolio. Despite a slight reduction in its price target by Scotiabank to $76, the stock still shows potential upside from current levels. The...
Micron Technology is investing $10 billion over the next decade to establish Micron Research Labs, a new division focused on future memory architectures and advanced semiconductor manufacturing. The company shows strong financial health with a low de...
Impact Biomedical Inc. will conduct a 1-for-12.62 reverse stock split on September 23, 2026, consolidating shares without changing shareholder value. This move facilitates its planned merger with Zoar Ltd., with a Form F-4 registration filed with the...
